WebDoctor Encyclopedia

Melanoma

Nodular melanoma

Nodular melanoma is a fast-growing type of melanoma that forms a raised, firm bump, often dark but sometimes pink or red, and may not follow the usual ABCDE warning signs.

Medically reviewed Last reviewed November 15, 2026

What is nodular melanoma?

Nodular melanoma (NM) is a type of cutaneous melanoma, the skin cancer that starts in the pigment-producing cells of the skin (melanocytes). It is the second most common subtype after superficial spreading melanoma and accounts for roughly 15% of melanomas, although the exact share varies between countries and studies.

What sets nodular melanoma apart is the way it grows. Most melanomas first spread sideways within the top layer of the skin for months or years. Nodular melanoma instead grows downwards into the deeper skin almost from the start, forming a raised lump. As a result, it is often already thick when it is found.

Because the thickness of a melanoma (its Breslow depth) is the most important factor for outlook, nodular melanoma causes a disproportionately large share of melanoma deaths. In New Zealand registry data, for example, nodular melanomas made up at least 15% of new melanomas but around half of melanoma deaths in the same year.

The good news is that a thin nodular melanoma removed early has an excellent outlook. Knowing what it looks like, and that it often does not follow the familiar ABCDE rules, is the key to finding it in time.

1. Epidemiology

Melanoma is most common in fair-skinned populations, with the highest rates in Australia and New Zealand, followed by northern and western Europe and North America. In the United States, melanoma of the skin is most often diagnosed between the ages of 65 and 74, and the median age at diagnosis is 67.

Nodular melanoma follows the same broad pattern, with a few typical features:

Feature What is typical for nodular melanoma
Share of all melanomas About 15%; second most common subtype after superficial spreading melanoma
Age Mostly middle-aged and older adults; thick tumours are more common in older people
Sex More common in men, who also tend to present with thicker tumours
Skin type Most common in very fair skin, but also occurs in people who tan easily and, less often, in darker skin
Body site Any skin site; most often the trunk, head and neck, and legs

Overall melanoma incidence has risen over recent decades in many countries, partly because of more sun exposure and partly because of better detection of thin melanomas. Thick melanomas, many of them nodular, have not fallen to the same extent, which is why nodular melanoma remains a focus of public education.

2. Causes and How the Disease Develops

2.1 Genetic changes in the tumour

Like other melanomas, nodular melanoma develops when melanocytes collect DNA changes that make them grow without control. Ultraviolet (UV) radiation from the sun and sunbeds is the main source of this DNA damage, and it leaves a typical “UV signature” in the tumour’s DNA.

The most common driver mutations in cutaneous melanoma are:

  • BRAF (usually V600E or V600K) – found in about half of cutaneous melanomas. Testing for it matters because BRAF-mutant melanoma can be treated with targeted drugs.
  • NRAS – found in about 15-25% of melanomas and relatively more frequent in nodular tumours.
  • NF1 – found mainly in melanomas from heavily sun-damaged skin.

2.2 Vertical growth from the start

In superficial spreading melanoma, there is usually a long “radial growth phase” in which the cancer cells stay in or just below the epidermis. In nodular melanoma this phase is very short or missing. The tumour enters the vertical growth phase early and invades the dermis, where it can reach lymphatic and blood vessels.

Nodular melanoma can arise on previously normal-looking skin or, less often, within an existing mole or another type of melanoma.

2.3 Risk factors

Category Risk factors
Skin and moles Fair skin that burns easily, red or blond hair, light eyes, many moles (especially more than 50), atypical moles
Sun and UV Sunburns, particularly in childhood; intense intermittent sun exposure; sunbed use
Personal and family history Previous melanoma or other skin cancer; melanoma in close relatives
Inherited genes High-risk mutations such as CDKN2A or CDK4; common MC1R variants linked to red hair and fair skin
Weakened immunity Organ transplant recipients, people with HIV, long-term immunosuppressive treatment
Age and sex Older age and male sex

People with nodular melanoma often have fewer moles than people with other melanoma subtypes, so a low mole count does not mean low risk for this type.

3. How does it look?

Nodular melanoma usually looks different from the flat, irregular, multicoloured mole that most people associate with melanoma. Knowing its typical appearance can prompt an earlier visit to a doctor.

3.1 Typical appearance

Feature Typical nodular melanoma
Shape Dome-shaped or polyp-like lump, often symmetrical
Elevation Clearly raised above the skin from early on
Feel Firm when touched
Colour Often a single colour: black, dark brown or blue-black; may also be red, pink or skin-coloured
Surface Smooth and shiny, or rough, crusted or warty; may break down (ulcerate) and bleed
Size Often larger than 6 mm, and frequently 1 cm or more by diagnosis, but it can be smaller
Border Usually well defined and regular

3.2 Why the ABCDE rule can miss it

The ABCDE rule (Asymmetry, Border irregularity, Colour variation, Diameter over 6 mm, Evolving) works well for superficial spreading melanoma. Nodular melanoma is often symmetrical, has a regular border and is a single colour, so it may “pass” the first three criteria.

For this reason, dermatologists use the EFG rule for raised lesions:

  • E – Elevated: the spot is raised above the skin.
  • F – Firm: it feels firm to the touch.
  • G – Growing: it has been growing steadily for more than about a month.

Any new lump with these three features should be checked by a doctor promptly.

3.3 Amelanotic (pink) nodular melanoma

About one-third of nodular melanomas contain little or no pigment. They appear as a pink, red or skin-coloured bump and can easily be mistaken for a harmless lesion such as a cyst, a pyogenic granuloma, a wart or a basal cell carcinoma. Because they are not dark, they are often diagnosed later and thicker.

3.4 Dermoscopic features

A dermatoscope (a handheld magnifier with a light) helps doctors look beneath the skin surface. A large international study of nodular melanoma found that it often lacks the classic features of other melanomas, such as an irregular pigment network. Features that raise suspicion include:

  • Blue-black colour and structureless blue or black areas
  • Blue-white veil (a blue area with a whitish, ground-glass haze)
  • Atypical or polymorphous blood vessels (dotted, linear-irregular or mixed vessel patterns)
  • Milky-red areas, which reflect new blood vessel formation, especially in pink tumours
  • Ulceration or a central crust

A rapidly growing, raised lesion that shows any of these features should be removed and examined under the microscope, whatever its size.

4. Symptoms

Early nodular melanoma often causes no symptoms at all. Most people notice it because they see or feel a new lump that keeps growing, often over weeks to a few months. In an Australian study, the fastest-growing melanomas, those thickening by 0.5 mm or more per month, were more often nodular, raised, symmetrical and lacking pigment.

4.1 Symptoms at the tumour site

Symptom What it may mean
A new or growing lump The most common reason people seek help
Change in colour Darkening, or new red, pink or blue areas
Itching or stinging Can occur in early or later stages
Bleeding or a sore that does not heal Often a sign of ulceration, which is linked to a worse outlook
Crusting or oozing Breakdown of the skin surface over the tumour
Tenderness or pain Less common; usually in larger tumours
Small dark or pink spots near the main lump May be satellite or in-transit metastases (melanoma spreading through skin lymph channels)

4.2 Symptoms of spread

If the melanoma spreads, symptoms depend on where it goes:

  • Lymph nodes – a firm, usually painless lump in the groin, armpit or neck, near the original tumour
  • Lungs – cough, shortness of breath or chest pain
  • Liver – pain under the right ribs, loss of appetite, yellowing of the skin
  • Brain – headaches, seizures, weakness, confusion or changes in vision or speech
  • Bones – persistent bone pain or fractures after minor injury
  • General – unexplained weight loss, tiredness and a general feeling of being unwell

These symptoms appear late. The aim of early detection is to find and remove the tumour long before they develop.

4.3 When to see a doctor

See a doctor or dermatologist promptly if you notice:

  • a new lump on the skin that is raised, firm and growing (the EFG signs)
  • a spot that looks different from your other moles (the “ugly duckling” sign)
  • a mole or bump that bleeds, crusts or itches without an obvious reason
  • a pink or red bump that keeps growing rather than settling within a few weeks

5. Diagnosis

5.1 Examination and biopsy

The doctor examines the lesion with the naked eye and a dermatoscope, checks the rest of the skin and feels the nearby lymph nodes.

The diagnosis is made by a biopsy. The preferred method is an excisional biopsy, which removes the whole lump with a narrow (1-3 mm) margin of normal skin. This allows the pathologist to measure the full thickness of the tumour. A partial (incisional or punch) biopsy may be used for very large lesions or difficult sites.

5.2 What the pathologist reports

Under the microscope, nodular melanoma shows a mass of atypical melanocytes in the dermis with little or no spread within the epidermis beyond the edge of the nodule. The pathology report includes:

  • Breslow thickness – measured in millimetres from the top of the skin to the deepest tumour cells; the most important prognostic factor
  • Ulceration – present or absent
  • Mitotic rate – how many dividing cells are seen per square millimetre
  • Margins – whether the tumour has been completely removed
  • Other features – lymphovascular invasion, microsatellites, tumour-infiltrating lymphocytes and regression

Special stains (immunohistochemistry) such as SOX10, S100, Melan-A and HMB-45 help confirm that the tumour is a melanoma, which is especially useful in amelanotic tumours.

5.3 Sentinel lymph node biopsy

A sentinel lymph node biopsy (SLNB) finds and removes the first lymph node(s) that drain the tumour site, to check for microscopic spread. It is usually done at the same time as the wider excision.

  • It is offered for melanomas thicker than 1.0 mm (T2 and above).
  • It is discussed and considered for melanomas 0.8-1.0 mm thick, or thinner ulcerated tumours (T1b).
  • It is generally not needed for thin, non-ulcerated melanomas under 0.8 mm (T1a) without other high-risk features.

5.4 Imaging and tests for spread

  • Stage I-IIA: routine scans are usually not needed.
  • Stage IIB-IIC: scans may be considered.
  • Stage III-IV: CT or PET-CT of the body and an MRI of the brain are usually recommended.
  • Ultrasound is used to examine lymph nodes.
  • Blood tests include lactate dehydrogenase (LDH), which is part of staging in stage IV disease.
  • Tumour testing for BRAF mutations is done in stage III-IV disease and in high-risk stage II, because it guides treatment.

6. Staging (AJCC 8th edition)

Melanoma is staged with the American Joint Committee on Cancer (AJCC) TNM system, 8th edition. The T category depends on Breslow thickness and ulceration:

T category Thickness Ulceration
Tis Melanoma in situ (confined to the epidermis) –
T1a Less than 0.8 mm No
T1b Less than 0.8 mm with ulceration, or 0.8-1.0 mm with or without ulceration Yes or no
T2a / T2b More than 1.0 to 2.0 mm No / Yes
T3a / T3b More than 2.0 to 4.0 mm No / Yes
T4a / T4b More than 4.0 mm No / Yes

Because nodular melanoma grows vertically, it is more often T2 or thicker at diagnosis than other subtypes.

The N category describes spread to regional lymph nodes and to the skin or lymph channels between the tumour and the nodes (satellite and in-transit metastases). The M category describes distant spread and whether LDH is raised.

The stage groups and the melanoma-specific survival reported in the international database used to develop the AJCC 8th edition are shown below:

Stage Main criteria 5-year melanoma-specific survival 10-year melanoma-specific survival
0 Tis, no spread – –
IA T1a, no spread 99% 98%
IB T1b or T2a, no spread 97% 94%
IIA T2b or T3a, no spread 94% 88%
IIB T3b or T4a, no spread 87% 82%
IIC T4b, no spread 82% 75%
IIIA Thin primary with limited microscopic nodal spread 93% 88%
IIIB Intermediate combinations of T and N 83% 77%
IIIC Thicker primary and/or more extensive nodal spread 69% 60%
IIID T4b with extensive nodal or in-transit spread 32% 24%
IV Distant metastasis (M1a-M1d) Not reported in AJCC 8th edition; improved markedly with modern treatment –

These figures come from patients treated before modern adjuvant drugs were available, and some population cohorts have reported lower survival. They describe melanoma as a whole, not nodular melanoma specifically, and cannot predict the outcome for any one person.

7. Treatment

Treatment depends on the stage, the BRAF status of the tumour, the patient’s general health and their wishes. It is planned by a multidisciplinary team.

7.1 Surgery

Wide local excision is the main treatment for melanoma that has not spread. After the diagnostic biopsy, the scar is re-excised with a safety margin of normal skin:

Breslow thickness Recommended clinical margin
In situ 0.5-1 cm
Up to 1.0 mm 1 cm
More than 1.0 to 2.0 mm 1-2 cm
More than 2.0 mm 2 cm

Margins may be adjusted on the face, ears, hands and feet to preserve function and appearance.

If the sentinel node contains melanoma, a completion lymph node dissection used to be routine. The MSLT-II trial showed that removing all the remaining nodes did not improve melanoma-specific survival compared with regular ultrasound monitoring. Most patients now have nodal surveillance instead, often combined with adjuvant drug treatment.

When lymph nodes are clearly involved on examination or scans, a therapeutic lymph node dissection is performed. Increasingly, immunotherapy is given before surgery (neoadjuvant treatment). In the NADINA trial, two cycles of nivolumab plus ipilimumab before surgery led to better event-free survival than surgery followed by adjuvant nivolumab.

7.2 Adjuvant treatment after surgery

For people at high risk of recurrence, drug treatment after complete removal lowers the chance of the melanoma coming back:

  • Anti-PD-1 immunotherapy – nivolumab or pembrolizumab for about one year after complete removal of stage III melanoma (nivolumab also after removal of stage IV disease). Both are also approved for stage IIB and IIC disease (pembrolizumab by the FDA in 2021, nivolumab in 2023).
  • Dabrafenib plus trametinib – for one year in BRAF V600-mutant stage III melanoma. In the COMBI-AD trial, this combination clearly reduced the risk of recurrence compared with placebo.

7.3 Treatment of advanced (unresectable or metastatic) melanoma

Treatment Examples Key facts
Anti-PD-1 immunotherapy Pembrolizumab, nivolumab First approved for advanced melanoma in 2014 (US) and 2015 (EU); standard first-line options
Anti-CTLA-4 immunotherapy Ipilimumab Approved in 2011; now mostly used in combination with nivolumab
Combined immunotherapy Nivolumab plus ipilimumab In CheckMate 067, about half of patients were alive at 5 years, and about a third at 10 years; more side effects than single drugs
Anti-PD-1 plus anti-LAG-3 Nivolumab plus relatlimab (fixed-dose combination) Approved in 2022 (US and EU; in the EU for tumours with PD-L1 below 1%); longer progression-free survival than nivolumab alone in RELATIVITY-047
BRAF plus MEK inhibitors Dabrafenib + trametinib, vemurafenib + cobimetinib, encorafenib + binimetinib Only for BRAF V600-mutant melanoma; rapid responses, but resistance often develops
Oncolytic virus Talimogene laherparepvec (T-VEC) Approved in 2015 for injection into skin, soft tissue and lymph node deposits that cannot be removed surgically
Tumour-infiltrating lymphocyte (TIL) therapy Lifileucel Approved by the FDA in 2024 for melanoma that has progressed after anti-PD-1 treatment (and a BRAF inhibitor if BRAF-mutant); in some European centres TIL therapy is produced locally
Chemotherapy Dacarbazine, carboplatin with paclitaxel Now used mainly when other options have failed

Immunotherapy can cause immune-related side effects, where the immune system attacks healthy organs such as the bowel, liver, lungs, skin, thyroid or pituitary gland. Most can be treated if they are reported early, so patients are asked to tell their team promptly about new symptoms.

7.4 Radiotherapy and local treatments

Radiotherapy is not usually used for the primary tumour, but it has a role in selected situations:

  • after lymph node surgery when the risk of the cancer coming back in the same area is high
  • for brain metastases, using stereotactic radiosurgery
  • to relieve pain from bone metastases or other symptoms

Isolated limb infusion or perfusion and surgical removal of single metastases may be used for selected patients.

7.5 Follow-up

Follow-up aims to detect recurrence and new primary melanomas early. A typical schedule is:

  • Years 1-3: skin and lymph node examination every 3-6 months, depending on stage
  • Years 4-5: every 6-12 months
  • After 5 years: at least yearly skin examination, often for life

People with stage IIB disease or higher may also have regular scans during the first years. Monthly self-examination of the skin and lymph nodes is recommended for everyone who has had melanoma.

8. Prognosis

The outlook for nodular melanoma depends mainly on its stage at diagnosis. Much of its poorer reputation comes from the fact that it is so often found when already thick. Whether it is more aggressive than other subtypes of the same thickness is still debated.

In US data from the SEER programme, the 5-year relative survival for all melanoma of the skin is:

SEER stage 5-year relative survival
Localised (confined to the skin) Over 99%
Regional (spread to nearby lymph nodes or tissues) About 76%
Distant (spread to distant organs) About 35%

8.1 Factors that affect the outlook

Factor Effect
Breslow thickness The strongest predictor: the thicker the tumour, the higher the risk of spread
Ulceration Worsens the outlook at every thickness and moves the tumour into a higher stage group
Sentinel node status Spread to the sentinel node is one of the strongest predictors of recurrence
Mitotic rate A higher rate is linked with a worse outlook
Site of distant spread and LDH Brain metastases and raised LDH are associated with poorer survival
Age and sex Older people and men tend to have worse outcomes, partly because their tumours are thicker
Response to treatment People with a complete response to immunotherapy often stay well for many years

Before modern immunotherapy and targeted drugs, median survival for stage IV melanoma was well under a year. Today a substantial proportion of people with advanced melanoma live for many years, and some appear to be cured.

9. Prevention and Early Detection

Not every nodular melanoma can be prevented, but the risk can be reduced and the tumour can be found earlier:

Step What to do
Sun protection Seek shade at midday; wear clothing, a wide-brimmed hat and sunglasses; use SPF 30+ broad-spectrum sunscreen, reapplied every 2 hours.
Avoid sunbeds IARC classes tanning devices as carcinogenic (Group 1).
Monthly self-checks Use a mirror or a partner; look for new or changing spots using EFG as well as ABCDE.
Regular skin checks For high-risk people: previous melanoma, many or atypical moles, family history, weak immunity.
Genetic counselling If several relatives have had melanoma, or one person has had several.

Raising awareness that melanoma can appear as a new, firm, growing lump, sometimes pink rather than dark, is one of the most effective ways to catch nodular melanoma earlier.

10. Frequently Asked Questions

Question Answer
Can nodular melanoma be pink or skin-coloured? Yes. About one-third of nodular melanomas have little or no pigment. A pink or red bump that keeps growing should be checked.
How fast does it grow? Nodular melanoma is among the fastest-growing melanomas. Many people notice a change over weeks to a few months.
Does it always start in an existing mole? No. Most nodular melanomas appear on previously normal-looking skin.
Can it appear on skin that is not exposed to the sun? Yes. It is most common on sun-exposed areas such as the head, neck, back and legs, but it can occur on skin usually covered by clothing.
Is the biopsy painful? The biopsy is done under local anaesthetic, so you feel only the injection. The wound may be sore for a few days.
Is there a blood test for early detection? No. Diagnosis depends on examining the skin and on biopsy. LDH is measured mainly in advanced disease.
Can nodular melanoma come back after surgery? It can, especially if the tumour was thick, ulcerated or had spread to lymph nodes. Regular follow-up and adjuvant treatment for high-risk cases reduce this risk or detect recurrence early.

11. Conclusion

Nodular melanoma is a fast-growing form of melanoma that pushes down into the skin early and often looks like a firm, symmetrical, dark or pink lump rather than a classic irregular mole.

Because it can slip past the ABCDE rule, the EFG signs – elevated, firm and growing – are the best warning. Thin tumours removed promptly are almost always cured.

For thicker or advanced disease, sentinel node biopsy, modern immunotherapy, BRAF-targeted treatment and newer options such as TIL therapy have transformed the outlook over the past 15 years.

Resources

  1. Gershenwald, J.E. et al. (2017) ‘Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual’, CA: A Cancer Journal for Clinicians, 67(6), pp. 472-492.
  2. Chamberlain, A.J., Fritschi, L. and Kelly, J.W. (2003) ‘Nodular melanoma: patients’ perceptions of presenting features and implications for earlier detection’, Journal of the American Academy of Dermatology, 48(5), pp. 694-701.
  3. Menzies, S.W. et al. (2013) ‘Dermoscopic evaluation of nodular melanoma’, JAMA Dermatology, 149(6), pp. 699-709.
  4. Liu, W. et al. (2006) ‘Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas’, Archives of Dermatology, 142(12), pp. 1551-1558.
  5. Faries, M.B. et al. (2017) ‘Completion dissection or observation for sentinel-node metastasis in melanoma’, New England Journal of Medicine, 376(23), pp. 2211-2222.
  6. Long, G.V. et al. (2017) ‘Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma’, New England Journal of Medicine, 377(19), pp. 1813-1823.
  7. Larkin, J. et al. (2019) ‘Five-year survival with combined nivolumab and ipilimumab in advanced melanoma’, New England Journal of Medicine, 381(16), pp. 1535-1546.
  8. National Cancer Institute (2026) Melanoma Treatment (PDQ®) – Health Professional Version. Available at: https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq (Accessed: October 2026).
  9. National Cancer Institute SEER Program (2026) Cancer Stat Facts: Melanoma of the Skin. Available at: https://seer.cancer.gov/statfacts/html/melan.html (Accessed: October 2026).
  10. DermNet (2026) Nodular melanoma. Available at: https://dermnetnz.org/topics/nodular-melanoma (Accessed: October 2026).

Prepared by the editorial team, October 2026.